Utility of Pretreatment Blood Platelet-To-Lymphocyte Ratio in Prediction of Clinical Outcomes and Chemosensitivity in Patients with Advanced Gastric Cancer: A Meta-Analysis

Xiulan Peng; Wei Zeng; Bing Tang; Anbing He; Min Zhang; Renfeng Luo

doi:10.12659/MSM.933449

31 January 2022 : Meta-Analysis

Utility of Pretreatment Blood Platelet-To-Lymphocyte Ratio in Prediction of Clinical Outcomes and Chemosensitivity in Patients with Advanced Gastric Cancer: A Meta-Analysis

Xiulan Peng^1AE*, Wei Zeng^2BF, Bing Tang^3CF, Anbing He^1B, Min Zhang^1B, Renfeng Luo^4AB

DOI: 10.12659/MSM.933449

Med Sci Monit 2022; 28:e933449

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 3 Forest plots for the association platelet to lymphocyte ratio and disease-free survival in patients with advanced gastric cancer (HR=1.47, 95% CI=1.14–1.88, P=0.003). CI – confidence interval; HR – hazard ratio.

Back to the Article

Utility of Pretreatment Blood Platelet-To-Lymphocyte Ratio in Prediction of Clinical Outcomes and Chemosensitivity in Patients with Advanced Gastric Cancer: A Meta-Analysis

Your Privacy